Compare Honest Company Inc (HNST) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Honest Company Inc trades at $5.05 (market cap $557.34M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 8.8× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HNST | TVTX | |
|---|---|---|
Market Cap | $557.34M | $4.88B |
Volume | 749,013 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $67.52 |
52-Week Low | $2.10 | $26.79 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $460.95M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.07, down 1.74% today, with mixed technical signals showing a neutral overall trend. The company reported Q2 2026 earnings beat with $0.04 EPS versus $0.00926 expected, though revenue declined year-over-year to $371.32M in 2025. Recent news highlights institutional buying from BlackRock and Deutsche Bank, while Seeking Alpha notes the company's turnaround progress through strategic exits and cost reductions.
The stock faces headwinds from negative profitability metrics (-3.56% net margin, -6.87% ROE) and elevated P/E of 48.83, but analyst consensus targets $5.30 with 30% buy ratings. Key risks include continued margin pressure and competitive threats in personal care, while potential upside hinges on sustained operational improvements and market share gains.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
